基础医学与临床 ›› 2008, Vol. 28 ›› Issue (12): 1329-1331.

• 短篇综述 • 上一篇    下一篇

雷帕霉素在免疫抑制和肿瘤抑制中的双重作

米蕊芳 张宏冰   

  1. 中国医学科学院基础医学研究所 北京协和医学院基础医学院 中国医学科学院基础医学研究所 北京协和医学院基础医学院
  • 收稿日期:2001-09-18 修回日期:1900-01-01 出版日期:2008-12-25 发布日期:2008-12-25
  • 通讯作者: 米蕊芳

Dual Effects of Rapamycin on Immuno-suppression and Tumor Inhibition

Rui-fang MI, Hong-bing ZHANG   

  1. Institute of Basic Medical Sciences, Peking Union Medical College Institute of Basic Medical Sciences, Peking Union Medical College
  • Received:2001-09-18 Revised:1900-01-01 Online:2008-12-25 Published:2008-12-25
  • Contact: Rui-fang MI,

摘要: 雷帕霉素(rapamycin)是近年来应用较多的免疫抑制剂,它在肿瘤治疗中也发挥重要作用。雷帕霉素(rapamycin)与FKBP12结合,形成Rapamycin- FKBP12复合物,这一复合物抑制mTOR (mammalian target of rapamycin)的活性,进一步抑制mTOR下游的一系列分子的合成或功能。雷帕霉素可将免疫细胞滞留于G1期,阻止免疫细胞的增殖;抑制IL-2和其他的免疫分子的合成,从而发挥其免疫抑制作用。另一方面,对于肿瘤细胞,雷帕霉素抑制其生长和增殖,发挥肿瘤抑制作用。它的这一双重功能可应用在器官移植和肿瘤治疗的交叉领域。

Abstract: Rapamycin is used frequently as an immunosuppressive agent and also plays an important role in tumor suppression. It complexes with FKBP12 to inhibit the serine/threonine protein kinase mammalian target of rapamycin (mTOR), the activation of which is required for protein synthesis and cell-cycle progression. Rapamycin can block cell cycle at G1 phase and inhibit cell proliferation. Furthermore rapamycin may inhibit cytokine production and cytokine signaling. Therefore rapamycin is increasingly used in the treatment of post-transplantation organ rejection and tumor therapy due to its dual effects of immuno-suppression and tumor inhibition.